No Data
Express News | Intellia Therapeutics Q1 Collaboration Revenue USD 28.935 Million
Express News | Intellia Therapeutics Q1 Operating Expenses USD 142.938 Million
Press Release: Intellia Therapeutics Announces First Quarter 2024 Financial Results and Highlights Recent Company Progress
Intellia Therapeutics Announces First Quarter 2024 Financial Results and Highlights Recent Company Progress -- Rapidly enrolling patients in the Phase 3 MAGNITUDE trial of NTLA-2001 for the
Intellia Therapeutics 1Q Loss/Shr $1.12 >NTLA
Intellia Therapeutics 1Q Loss/Shr $1.12 >NTLA
Why Intellia Therapeutics, Inc. (NTLA) Outpaced the Stock Market Today
Intellia Therapeutics to Hold Conference Call to Discuss First Quarter 2024 Earnings and Company Updates
CAMBRIDGE, Mass., May 02, 2024 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies, will present